LINGO1-Targeted Antibody-Drug Conjugates Show Preclinical Efficacy and Tolerability in Ewing Sarcoma Models
Key Insights
LINGO1 (search) was identified as a selective cell-surface target enriched in Ewing sarcoma (search) cells through a stepwise prioritization strategy across multiple proteomic datasets.
Opicinumab-MMAE (search) ADCs suppressed Ewing sarcoma (search) tumor growth in xenograft models without overt toxicity, while free MMAE (search) caused rapid body weight loss requiring early study termination.
A single dose of opicinumab-MMAE (search) achieved more sustained tumor control compared with irinotecan, with no detectable liver or brain toxicity.
Ewing sarcoma (search), an aggressive pediatric cancer that develops in bones and soft tissues, accounts for approximately 1% of pediatric cancers and carries a critical unmet need for targeted therapies. While standard-of-care chemotherapy achieves roughly a 70% success rate, intensive multicycle regimens substantially compromise quality of life and increase the risk of treatment-related secondary morbidities. Now, researchers at the University of North Carolina at Chapel Hill have demonstrated that antibody-drug conjugates (ADCs) targeting the cell-surface protein LINGO1 (search) can selectively deliver potent cytotoxic payloads to Ewing sarcoma tumors while sparing healthy tissues in preclinical models.
The findings, published in the Journal of Clinical Investigation, represent a significant step toward addressing the long-standing challenge of maintaining chemotherapy efficacy while diminishing the adverse effects that disproportionately affect young survivors, most of whom are diagnosed between ages 10 and 20.
A Systematic Search for Tumor-Specific Targets
The development of effective ADCs hinges on identifying cell-surface proteins that are highly expressed on tumor cells but largely absent from normal tissues. To this end, the research team applied a stepwise prioritization strategy, cross-referencing 883 plasma membrane proteins annotated in the Human Protein Atlas with 39 ubiquitously expressed Ewing sarcoma (search) surface proteins. This analysis yielded eight overlapping candidates, four of which are known EWS:FLI1 transcriptional targets, lending further support to their relevance.
To minimize off-tumor toxicity, the investigators assessed tumor specificity and found that only LINGO1 (search) (leucine-rich repeat and Ig domain–containing 1) and SLCO5A1 exhibited peak expression in bone cancer cell lines. LINGO1 expression outside Ewing sarcoma (search) was largely confined to brain tissue, where blood-brain barrier–restricted antibody access may limit toxicity, whereas SLCO5A1 was broadly expressed among tissues. The team therefore prioritized LINGO1 for further study.
LINGO1 (search) is a CNS-enriched, postnatally expressed transmembrane protein that functions within the Nogo receptor complex to regulate myelination and neuronal survival, a profile that minimizes concerns about developmental toxicity when therapeutically targeted. Cell-surface expression of LINGO1 was consistently detected in primary and relapsed Ewing sarcoma (search) patient-derived xenografts and confirmed by FACS analysis.
From SN-38 to MMAE (search): Optimizing the Payload
The LINGO1 (search) extracellular domain is recognized by the Li81 antibody, also known as opicinumab (BIIB033), which is currently in clinical trials for multiple sclerosis and undergoes lysosomal trafficking following endocytosis, enabling payload release. The researchers first tested opicinumab conjugated to SN-38 (DAR = 5.2), which induced LINGO1-dependent apoptosis in Ewing sarcoma (search) cells. However, a single opicinumab-SN38 injection only modestly delayed tumor growth in MHH-ES-1 xenografts without reaching statistical significance, likely reflecting limited payload exposure.
To overcome this limitation, the team replaced SN-38 with the more potent microtubule-disrupting agent monomethyl auristatin E (MMAE (search)), a payload already employed in five FDA-approved ADCs, including Adcetris, Polivy, Padcev, Tivdak, and Aidixi (RC48). The synthesized opicinumab-MMAE (search) ADCs (DAR = 4.6) were then evaluated in MHH-ES-1 xenograft-bearing mice.
The results were striking. Free MMAE (search), administered at the same molecular mass, caused rapid body weight loss that necessitated early termination of the study. In contrast, opicinumab-MMAE (search) ADCs at comparable payload doses showed no overt toxicity and significantly suppressed Ewing sarcoma (search) tumor growth. Half-dose opicinumab-MMAE efficacy was further validated in a TC-32 xenograft model.
Sustained Tumor Control and Favorable Biodistribution
Biodistribution analysis revealed marked enrichment of free MMAE (search) in tumors versus liver, brain, and serum seven days after opicinumab-MMAE (search) treatment. Compared with irinotecan, a single dose of opicinumab-MMAE achieved more sustained tumor control without detectable liver or brain toxicity, as measured by alanine aminotransferase (ALT) activity, and without body weight loss.
Pharmacokinetic analysis showed similar profiles for opicinumab and opicinumab-MMAE (search), with a terminal half-life (t1/2β) of approximately two days. Notably, released MMAE (search) levels were approximately four orders of magnitude lower than those of the intact ADC, underscoring the stability of the conjugate in circulation and its preferential payload release within tumors.
Next Steps and Future Directions
The authors conclude that LINGO1 (search) represents a selective and therapeutically actionable cell-surface target in Ewing sarcoma (search) and that LINGO1-targeted ADCs demonstrate preclinical efficacy and tolerability warranting further investigation. The researchers indicate that next steps will include evaluation in immunocompetent mouse models and patient cohorts, as well as exploration of LINGO1-directed cellular therapies such as CAR T cells.
The study was supported by the North Carolina Biotechnology Center Flash Grant, a Department of Defense Congressionally Directed Medical Research Programs Idea Development Award, and the University of North Carolina at Chapel Hill University Cancer Research Fund. The authors declared no conflicts of interest.